<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044655</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 98-924</org_study_id>
    <secondary_id>R01MH059312</secondary_id>
    <nct_id>NCT00044655</nct_id>
  </id_info>
  <brief_title>Switching Medication to Treat Schizophrenia</brief_title>
  <official_title>Effectiveness of Switching Antipsychotic Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of switching medications in decreasing
      schizophrenia symptoms in individuals who are currently taking an antipsychotic medication
      for the treatment of schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past several years, new, &quot;atypical&quot; antipsychotic medications have become available
      to treat schizophrenia with little information to guide prescribing for relatively stable
      outpatients.

      Participants will be randomly assigned to either continue taking their current medications
      for schizophrenia, or to switch to a new medication. Participants assigned to switch to a new
      medication will begin receiving either olanzapine (Zyprexa), risperidone (Risperdal),
      ziprasidone (Geodon), quetiapine (Seroquel), or aripiprazole (Abilify), depending on what
      they are currently taking. Participants currently taking a single oral medication will switch
      to olanzapine, risperidone, ziprasidone, quetiapine, or aripiprazole. Participants currently
      taking a single conventional injectable will begin taking long-acting injectable risperidone
      (Risperdal Consta). Participants currently taking two antipsychotic medications will begin
      taking only one of the medications they are currently using. Participants will stay on their
      assigned treatment for 6 months, after which time the participant's prescribing psychiatrist
      will advise the participant on which medication should be used. Study participants are
      interviewed at study start and at follow-up visits for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Who Discontinued Medication Within First 6 Study Months</measure>
    <time_frame>Measured at Six Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Symptoms, Hospitalization, and Medication Side Effects</measure>
    <time_frame>Measured at Year 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Stay on baseline medication prescribed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch per study protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>As prescribed by routine prescriber (not dictated by study protocol)</description>
    <arm_group_label>Stay on baseline medication prescribed</arm_group_label>
    <arm_group_label>Switch per study protocol</arm_group_label>
    <other_name>Risperdal, Risperdal Consta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>As prescribed by routine prescriber (not dictated by study protocol)</description>
    <arm_group_label>Stay on baseline medication prescribed</arm_group_label>
    <arm_group_label>Switch per study protocol</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>As prescribed by routine prescriber (not dictated by study protocol)</description>
    <arm_group_label>Stay on baseline medication prescribed</arm_group_label>
    <arm_group_label>Switch per study protocol</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>As prescribed by routine prescriber (not dictated by study protocol)</description>
    <arm_group_label>Stay on baseline medication prescribed</arm_group_label>
    <arm_group_label>Switch per study protocol</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>As prescribed by routine prescriber (not dictated by study protocol)</description>
    <arm_group_label>Stay on baseline medication prescribed</arm_group_label>
    <arm_group_label>Switch per study protocol</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  SCID diagnosis of schizophrenia or schizoaffective disorder

          -  Partially remitted outpatients, defined as persons who have received clear symptomatic
             benefit from antipsychotic medication but remain symptomatic (due to lack of efficacy
             or inability to tolerate an efficacious dose) or suffer significant side effects

          -  Treatment with antipsychotic medications for at least 2 months

          -  Received at least 1 outpatient mental health service every 3 months for the past 6
             months

        Exclusion criteria:

          -  Severe symptoms or side effects that indicate the necessity for a medication change

          -  Currently taking 3 or more antipsychotic medications for ongoing daily administration
             (PRN medications and mood stabilizers are allowable)

          -  Treatment with clozapine

          -  One or more nights spent in a psychiatric hospitalization within the past 3 months

          -  Received services from a crisis intervention program within the past 3 months

          -  Require placement in a skilled nursing facility as a result of a physical condition or
             disability

          -  Criminal charges pending (once charges clear, the person will be considered)

          -  Pregnant or breast feeding

          -  Contraindication to any of the medications to which the patient might be assigned
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M. Essock, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, Essock SM; Schizophrenia Trials Network. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6.</citation>
    <PMID>22480442</PMID>
  </results_reference>
  <results_reference>
    <citation>Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2.</citation>
    <PMID>21536693</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2002</study_first_submitted>
  <study_first_submitted_qc>September 4, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2002</study_first_posted>
  <results_first_submitted>September 27, 2013</results_first_submitted>
  <results_first_submitted_qc>September 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2013</results_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stay</title>
          <description>Participants will continue taking medication prescribed at study entry</description>
        </group>
        <group group_id="P2">
          <title>Switch</title>
          <description>Participants will change medications from medication prescribed at study entry</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stay</title>
          <description>Participants will continue taking medication prescribed at study entry</description>
        </group>
        <group group_id="B2">
          <title>Switch</title>
          <description>Participants will change medications from medication prescribed at study entry</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="10.4"/>
                    <measurement group_id="B2" value="47.7" spread="11.3"/>
                    <measurement group_id="B3" value="46.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Who Discontinued Medication Within First 6 Study Months</title>
        <time_frame>Measured at Six Months</time_frame>
        <population>intent to treat samples for 2 substudies: injectable to injectable and polypharmacy to monotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Stay</title>
            <description>Participants will continue taking medication prescribed at study entry</description>
          </group>
          <group group_id="O2">
            <title>Switch</title>
            <description>Participants will change medications from medication prescribed at study entry</description>
          </group>
        </group_list>
        <measure>
          <title>Number Who Discontinued Medication Within First 6 Study Months</title>
          <population>intent to treat samples for 2 substudies: injectable to injectable and polypharmacy to monotherapy</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychiatric Symptoms, Hospitalization, and Medication Side Effects</title>
        <time_frame>Measured at Year 1</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stay</title>
          <description>Participants will continue taking medication prescribed at study entry</description>
        </group>
        <group group_id="E2">
          <title>Switch</title>
          <description>Participants will change medications from medication prescribed at study entry</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Site PI learned that the 69 year old participant had died following recurrent episodes of bleeding from cerebral aneurism that was diagnosed, but unknown to the site PI, prior to study enrollment (randomized to injectable risperidone)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Hospitalization</sub_title>
                <description>Following medication change, participant's prescriber called Project Director to report that the participant was not doing well and was hospitalized subsequent to symptom exacerbation; prescriber changed client's antipsychotic medication regime.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy H. Covell, Ph.D.</name_or_title>
      <organization>NYSPI</organization>
      <phone>6469450227</phone>
      <email>covelln@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

